Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
GLAXOSMITHKLINE NZ LIMITED,Dostarlimab,"Endometrial cancer, advanced or recurrent, with deficient mismatch repair (dMMR) status, first line",Dostarlimab (Jemperli),Options for investment,Hospital,Oncology Agents and Immunosuppressants
